Kazia Therapeutics (KZIA) Advances Epilepsy Trial, Market Pricing Reflects High Growth Expectations
· gurufocus.com
On September 22, 2026, Kazia Therapeutics Ltd (NASDAQ: KZIA) announced a significant milestone as its licensed partner Sovargen administered the first dose in a
On September 22, 2026, Kazia Therapeutics Ltd (NASDAQ: KZIA) announced a significant milestone as its licensed partner Sovargen administered the first dose in a...